1. At a Glance – The “Quiet Kid” of Indian APIs
Anuh Pharma is that student who sits on the last bench, never raises their hand, never trends on Twitter, yet somehow keeps scoring 70–80 marks every single year. No drama. No debt. No fancy investor decks. Just APIs, exports, and cash quietly piling up.
As of 6 Feb 2026, Anuh Pharma trades at ₹79.3, with a market cap of ~₹795 Cr, a P/E of ~19x, and a dividend yield of ~1.9% — which in today’s “growth-only-no-cash” market already makes it an uncle stock.
But here’s the twist: Q3 FY26 revenue grew 23.6% YoY, PAT jumped 30% YoY, and the company is virtually debt-free.
Sales are up, margins are stable, regulatory approvals keep coming, and promoters sit comfortably at 71.8% holding with zero pledging.
Yet the stock is down 22% over 1 year.
So what’s going on here?
Is this a boring but beautiful cash machine… or just another API company stuck in low-margin hell?
Let’s put on our funny-auditor glasses and open the books.
2. Introduction – APIs, Antibiotics & Absolutely No Flash
Anuh Pharma was incorporated in 1960, which means it has survived socialist India, license raj, liberalisation, global pharma cycles, China dumping, COVID chaos, and still decided to stay… boring.
And that’s not an insult.
The company operates in bulk drugs / APIs, a space where glamour goes to die but cash flows are very much alive. It is part of the SK Group and focuses heavily on macrolides and anti-TB APIs — not exactly Instagram-friendly molecules, but ones that hospitals and governments keep ordering year after year.
Unlike many pharma peers chasing biosimilars, specialty injectables, or US generics with FDA anxiety attacks every quarter, Anuh Pharma sticks to:
- Antibiotics
- Anti-TB
- Corticosteroids
- Anti-diabetics
- Old but essential molecules
This is the rice-dal-sabzi of pharma, not the avocado toast.
The result?
Predictable demand, moderate margins, fewer regulatory heart attacks, and steady dividends.
But in a market obsessed with 30% EBITDA margins and “next big molecule” stories, such companies often get ignored — until they don’t.
3. Business Model – WTF Do They Even Do?
Let’s simplify this for your friend who thinks “API” means software.
Anuh Pharma manufactures active pharmaceutical ingredients — the raw chemical compounds that pharma companies convert into tablets, syrups, and injections.
Core focus areas:
- Macrolides (like Erythromycin, Azithromycin)
- Anti-TB drugs (Pyrazinamide, Isoniazid)
- Anti-infectives & steroids
- Anti-diabetic molecules (Gliclazide, Dapagliflozin, etc.)
The company claims:
- Largest producer of erythromycin salts in India
- Among top 5 globally
- Largest producer of Pyrazinamide worldwide
That’s not small talk. That’s global scale in niche molecules.
Manufacturing setup:
- WHO-GMP & EU-GMP compliant facility at Tarapur
- Total land: 11,400 sq. mtrs (including newly acquired
